Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

BACKGROUND: The introductions of anti‐ human epidermal growth factor receptor‐2 (HER2) agents have significantly improved the treatment outcome of patients with HER2‐positive breast cancer. BAT8001 is a novel antibody‐drug conjugate targeting human epidermal growth factor receptor‐2 (HER2)‐expressin...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ruoxi, Xia, Wen, Wang, Liye, Lee, Kaping, Lu, Qianyi, Jiang, Kuikui, Li, Shengfeng, Yu, Jinquan, Wei, Jin, Tang, Weijia, Zhou, Danyang, An, Xin, Huang, Jiajia, Xue, Cong, Bi, Xiwen, Shi, Yanxia, Yuan, Zhongyu, Xu, Fei, Wang, Shusen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896747/
https://www.ncbi.nlm.nih.gov/pubmed/33528890
http://dx.doi.org/10.1002/cac2.12135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896747/
https://www.ncbi.nlm.nih.gov/pubmed/33528890
http://dx.doi.org/10.1002/cac2.12135

Ejemplares similares